Table 3. Subgroup Analyses According to Severity of AD.
| Outcomes | AD cohort | Non-AD cohort | HR (95% CI)a | ||
|---|---|---|---|---|---|
| Events, No. | IRb | Events, No. | IRb | ||
| Venous thromboembolism | |||||
| Mild AD vs non-AD | 393 | 1.17 | 304 | 0.90 | 1.30 (1.12-1.51) |
| Severe AD vs non-AD | 567 | 0.98 | 418 | 0.73 | 1.35 (1.19-1.53) |
| Deep vein thrombosis | |||||
| Mild AD vs non-AD | 308 | 0.92 | 245 | 0.72 | 1.27 (1.07-1.50) |
| Severe AD vs non-AD | 467 | 0.81 | 350 | 0.61 | 1.32 (1.17-1.48) |
| Pulmonary embolism | |||||
| Mild AD vs non-AD | 106 | 0.31 | 74 | 0.22 | 1.44 (1.07-1.94) |
| Severe AD vs non-AD | 133 | 0.23 | 95 | 0.17 | 1.39 (1.07-1.81) |
Abbreviations: AD, atopic dermatitis; HR, hazard ratio; IR, incidence rate.
a
The HRs were calculated using a univariable Cox regression model with propensity score matching; the HR was calculated using the corresponding non-AD group as the reference.
b
Incidence rate per 1000 person-years.